A promising mRNA-based drug has shown early success in treating a rare genetic disorder by addressing its core deficiency. Reported in Nature, this breakthrough offers hope for mRNA technology beyond vaccines. Developed by Moderna, the therapy targets propionic acidaemia, restoring metabolic function in affected individuals. Initial trial results indicate a reduction in life-threatening episodes for participants, although statistical significance was not reached. Despite challenges such as mRNA’s short-lived nature and side effects, this advancement marks a significant step toward realizing the therapeutic potential of mRNA technology. Moderna is now expanding trials and exploring additional quality-of-life improvements in patients. Anecdotal evidence suggests positive outcomes, with one parent noting significant improvements in her daughter’s energy and focus after receiving the treatment.